Journal: Clinical and Translational Radiation Oncology

Article Title: Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear accelerator

doi: 10.1016/j.ctro.2026.101200

Figure Lengend Snippet: Representative axial (A-C) and sagittal (C) FLAIR images from three patients at fraction 0 (F0), fraction 15 (F15), fraction 30 (F30), and 1 month post-radiotherapy (PM1; diagnostic MRI), demonstrating patient-specific changes in T2/FLAIR region-of-interest (ROI) volume (V), percentage change in V relative to F0 (V rel ), and migration distance (d migrate ). The baseline ROI at F0 is outlined in pink; ROIs at F15, F30, and PM1 are outlined in dark blue. (A) Unmethylated tumor following gross total resection (GTR), without early progression, showing decreasing ROI volume with low d migrate across timepoints. (B) Unmethylated tumor following subtotal resection (STR), with early progression, showing increasing ROI volume with increasing d migrate across timepoints. (C) Methylated tumor following STR, without early progression, showing decreasing ROI volume with large d migrate across timepoints. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: For radiotherapy planning, all patients underwent MR simulation on a 1.5 T MRI scanner (Philips Ingenia) with gadolinium-enhanced T1-weighted, T2-weighted, diffusion-weight imaging (DWI), and fluid-attenuated inversion recovery (FLAIR) volumetric sequences.

Techniques: Diagnostic Assay, Migration, Methylation

Journal: Clinical and Translational Radiation Oncology

Article Title: Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear accelerator

doi: 10.1016/j.ctro.2026.101200

Figure Lengend Snippet: Longitudinal relative change in MR-Linac T2/FLAIR region of interest (ROI) volume from baseline (V rel , %) during radiotherapy by (a) fractionation regimen, (b) early progression status (progression ≤ 6 months after radiotherapy), (c) methylation status, and (d) combined early progression and methylation status. Dotted lines represent individual patients; solid lines indicate group medians. PM1 denotes the post-treatment MRI performed one month after radiotherapy and is shown separately for the 15-fraction and 30-fraction cohorts; patients treated with 15 fractions do not contribute data beyond F15.

Article Snippet: For radiotherapy planning, all patients underwent MR simulation on a 1.5 T MRI scanner (Philips Ingenia) with gadolinium-enhanced T1-weighted, T2-weighted, diffusion-weight imaging (DWI), and fluid-attenuated inversion recovery (FLAIR) volumetric sequences.

Techniques: Fractionation, Methylation

Journal: Clinical and Translational Radiation Oncology

Article Title: Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear accelerator

doi: 10.1016/j.ctro.2026.101200

Figure Lengend Snippet: Longitudinal migration distance (d migrate , mm) of MR-Linac T2/FLAIR region of interest (ROI) during radiotherapy by (a) fractionation regimen, (b) early progression status (progression ≤ 6 months after radiotherapy), (c) methylation status, and (d) combined early progression and methylation status. Dotted lines show individual patients; solid lines indicate group medians. PM1 denotes the post-treatment MRI performed one month after radiotherapy and is shown separately for the 15-fraction and 30-fraction cohorts; patients treated with 15 fractions do not contribute data beyond F15.

Article Snippet: For radiotherapy planning, all patients underwent MR simulation on a 1.5 T MRI scanner (Philips Ingenia) with gadolinium-enhanced T1-weighted, T2-weighted, diffusion-weight imaging (DWI), and fluid-attenuated inversion recovery (FLAIR) volumetric sequences.

Techniques: Migration, Fractionation, Methylation